Stoke Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2024 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Stoke Therapeutics, Inc. quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2024 to Q3 2025.
- Stoke Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was -$39.6M, a 49.9% decline year-over-year.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)